Stock Alert: CureVac Slips 13%

Shares of German biopharmaceutical company CureVac N.V. (CVAC) are down 13 percent on Tuesday's trading on reports that the European Medicines Agency will not take a decision on the approval of the company's COVID-19 vaccine before August.

Earlier, the company had said that a late-stage trial including 40,000 volunteers in Europe and Latin America had reached a first interim analysis at 59 COVID-19 cases, but more data would be needed for statistically reliable efficacy numbers.

The stock is currently trading at $108.30, down $16.70 or 13% on the NASDAQ.

CVAC has traded between $36.15 and $151.80 during the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Biotech Stocks by Subscribing to RTT Biotech Investor.
Follow RTT